Pearl River Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Pearl River Capital’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2	Closed	–	–	431
2018 Q4	$0	Buy	+2	New	+$399	﹤0.01%	806

Other funds holding CRBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Pearl River Capital's CRBP Position: Q1 2019 in Review

Pearl River Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2019, closing a stake of 2 shares.

Pearl River Capital first reported a position in CRBP in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 101 funds tracked by Wall St. Rank hold CRBP as of Q1 2019.

Pearl River Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 2 Corbus Pharmaceuticals shares in Q1 2019.
Pearl River Capital first reported a position in Corbus Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Corbus Pharmaceuticals position peaked at $0 in Q4 2018.
101 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.